Politics ❯ Healthcare Policy

Drug Pricing

Government Regulations US Government Senate Hearings Government Involvement U.S. Politics US Senate Consumer Access NHS Funding Equity Across Developed Countries Inflation Reduction Act Public Messaging Medicare Pharmaceutical Industry Pharmaceutical Regulations Provincial Regulations Political Pressure Regulatory Issues High-cost Drugs US Administration U.S. Policy Most-Favored-Nation Deals IVF Treatments Bernie Sanders Regulatory Environment Eli Lilly Pharmaceutical Companies Public Health

Johnson & Johnson Tops Q1 Forecasts and Lifts 2026 Outlook

Strong oncology growth offset Stelara’s drop.

Oz Defends Trump’s Drug-Price Math on NBC as Fact-Checks Reject Claims of Cuts Over 100 Percent

FDA Names First 9 Drugs for ‘National Priority’ Fast-Track Reviews, Targeting 1–2-Month Decisions

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks